HPV’nin Görünen Yüzü, Kondiloma Akuminata

Year 2020, Volume: 17 Issue: 4, 615 - 620, 31.12.2020

İrem Küçükyıldız , Ali Yanık

https://doi.org/10.38136/jgon.671667

Cited By: 1

Abstract

İnsan papilloma virüsü (HPV), seksüel geçişli hastalıkların en sık sebebi olarak gösterilen enfeksiyöz ajanlardır. 200 ün üzerinde tipi olarak başta anogenital bölge olmak üzere , orofarinks ve solunum sistemleri üzerinde benign lezyonlardan , preinvaziv ve invaziv lezyonlara kadar uzanan geniş bir hastalık yelpazesine sahiptir. Kondiloma akuminatanın gün geçtikçe artan insidansı HPV enfeksiyonları içerinde önemli bir paya sahip olmasını sağlamıştır. Kondiloma akuminata HPV nin görünen lezyonları olarak kabul edilir.
Kondiloma akuminata lezyonlarına yönelik, kişilerin kendi kendilerine uygulayabilecekleri ev tedavileri, anestezi altında uygulanan cerrahi tedaviler gibi birden çok tedavi yöntemi vardır. Tedavi seçiminde dikkat edilmesi gereken noktalar, bu enfeksiyonun persistansı ve tekrarlamasını engellemek için önemlidir.
Biz bu makale ile kondilomata aküminata lezyonlarına yaklaşımda bilinmesi gerekenler ve uygulanan tedavi yöntemlerini paylaşmak istedik.

Keywords

HPV, Kondiloma akuminata, anogenital siğil, imiqumod

References

• Dunne, E. F., & Park, I. U. (2013). HPV and HPV-associated diseases. Infectious Disease Clinics, 27(4), 765-778.
• de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324:17.
• Division of STD Prevention (1999). Prevention of genital HPV infection and sequelae: report of an external consultants' meeting. Atlanta, GA: Centers for Disease Control and Prevention www.cdc.gov/std/hpv/hpvsupplement99.pdf (Accessed on February 08, 2016).
• Kennedy CM, Boardman LA. New approaches to external genital warts and vulvar intraepithelial neoplasia. Clin Obstet Gynecol 2008; 51:518-526.
• Gall SA. Female genital warts: global trends and treatments. Infect Dis Obstet Gynecol 2001; 9:149-154.
• Burd, E. M., & Dean, C. L. (2016). Human Papillomavirus. Microbiology spectrum, 4(4).
• https://gco.iarc.fr/causes/infections/toolsbars?mode=2&sex=0&population=who&country=4&continent=
• Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2012;30:6016–9.
• Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 2013; 13:39.
• Ailyn Vidal, MD, Fabio Landoni, MD Condylomas & Evidence-Based Review of Medical and Surgical Treatments of Genital Warts.Textbook of Gynaecological Oncology Gunes Publishing 3rd edition,2016 ESGO, 223-229.
• Ozgul, N., Tuncer, M., Abacioglu, M., & Gultekin, M. (2011). Estimating prevalence of genital warts in Turkey: survey among KETEM-affiliated gynecologists across Turkey. Asian Pacific journal of cancer prevention: APJCP, 12(9), 2397-400.
• Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2006. MMWR 2006; 55 (RR-11):1-94.
• Mayeaux EJ, Dunton C. Modern management of external genital warts. Journal of Lower Genital Tract Disease 2008; 12:185-192.
• Jonathan S. Berek, Berek &Novak Jinekoloji 2017; s569
• Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosiswww.uptodate.com/
• & Sarkola ME, Grénman SE, Rintala MA, et al. Human papillomavirus in the placenta and umbilical cord blood. Acta Obstet Gynecol Scand 2008; 87:1181.
• Silverberg MJ, Thorsen P, Lindeberg H, et al. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003; 101:645.
• Gunter J. Genital and perianal warts: new treatment opportunities for human papilloma virus infection. Am J Obstet Gynecol 2003; 189:S3-S11.
• Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician 2004; 70:2335-2342.
• J Thomas Cox,MD ,Joel M Palefsky, MD , Human papillomavirus vaccination,www.uptodate.com/desktop
• Greene I. Therapy for genital warts. Dermatol Clin 1992; 10:253-267.
• Hurwitz DJ, Pincus L et al: Imiquimod a topically applied link between innate and acquired immunity. Arch Dermatol 2003;139:1349-50.
• Tyring S, Conant M, Marini M: Imiquimod; an international update on therapeutic uses in dermatology. Int J Dermatol 2002;41:810-6
• Sauder DN: Imiquimod: modes of action. Br J Dermatol 2003;149 (Suppl. 66): 5-8.
• Perry CM, Lamp HM: Topical imiquimod: a review of its use in gen- ital warts. Drugs 1999;58:375-90.
• Van Seters M, van Beurden M, ten Kate FJ, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. NEJM 2008; 358:1465-1473.
• Tatti S, Swinehart JM, Thielert C, et al. Sinecathechins, a defined green tea extract in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 2008; 111:1371-1379.
• Lacey, C. J. N., Woodhall, S. C., Wikstrom, A., & Ross, J. (2013). 2012 European guideline for the management of anogenital warts. Journal of the European Academy of Dermatology and Venereology, 27(3), e263-e270.
• Condylomata acuminata(anogenital warts) in children: www.uptodate.com/